The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Ascendis Pharma A/S (NASDAQ:ASND) is one of the

7 Best Strong Buy European Stocks to Invest In. On April 8, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective at the opening of trading on April 20. As part of the transition, all outstanding ADSs will be exchanged on a one-for-one basis for ordinary shares, which will continue trading under the ticker “ASND.”

Also on April 8, Ascendis Pharma reported new Week 52 data from the Phase 2 COACH trial evaluating combination therapy with once-weekly TransCon CNP and TransCon hGH in children with achondroplasia. The company said the data showed improvements beyond linear growth, including increases in arm span, spinal canal dimensions, and lower limb alignment. Mean changes in arm span Z-scores were +1.02 for treatment-naive patients and +0.66 for previously treated patients, with absolute gains of 9.4 cm and 7.9 cm, respectively. The company also reported improvements in interpedicular distance and tibial femoral angle, indicating potential benefits in reducing nerve compression and improving leg alignment, with all patients completing 52 weeks and remaining on therapy.

Copyright: wavebreakmediamicro / 123RF Stock Photo

On April 7, 2026, Ascendis Pharma announced that Yuviwel, its TransCon CNP therapy, was granted orphan drug exclusivity by the FDA and is now commercially available in the United States.

Ascendis Pharma A/S (NASDAQ:ASND) develops TransCon-based therapies for unmet medical needs.

While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.